1. Scrip
  2. >>Leadership

Narasimhan Promises To Improve Novartis' Image As Top Lawyer Exits

 
• By Sten Stovall

Novartis' top lawyer is taking responsibility for the controversial contract with Essential Consultants and stepping down, amid pledges by the company to polish its tarnished image.

Broom
Novartis' CEO Narasimhan Is Promising To Be An Effective New Broom There • Source: Shutterstock

Novartis AG’s top lawyer Felix Ehrat is taking the fall for the controversial $1.2m in payments he helped arrange to Donald Trump’s attorney, as the Swiss group's newly installed CEO makes fresh promises to clean up the company's ethical act.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

More from Scrip

In Brief: Genmab To Seek FDA Nod For Epkinly In Lymphoma

 
• By Sushmita Panda

Genmab will submit an sBLA for Epkinly in R/R follicular lymphoma in H1 2025, backed by positive Phase III data.

Pharma Predicts Modest Impact From Tariffs, But It Depends On What Comes Next

 
• By Jessica Merrill

Drugmakers aren’t expecting a big financial hit from tariffs for now, but a report commissioned by PhRMA suggests the cost of pharma-sector tariffs could be steep.

OPPI’s Matai On Section 3(d) Of India’s Patent Regulations: Now’s The Time To Open Up

 
• By Anju Ghangurde

Anil Matai, director general, Organization of Pharmaceutical Producers of India, talks in this audio interview about the evolving intellectual property landscape in India post the 2024 amendments, including long-standing sticking points such as Section 3(d) of India’s patent regulations and innovator firms' experience of the Bolar provision. There’s also a "compelling reason" to consider regulatory data protection, he claims.